Fig. 4: Anti-S1 IgG levels over time between first vaccine dose and serosurvey by severity of acute infection.
A Unadjusted anti-S1 IgG levels by acute infection severity and time between first vaccine dose and dried blood spot collection categorized by quartiles in complete case cohort of participants with infection history and anti-S1 levels (n = 3995). Quartile 1 (no infection [n = 1298], non-hospitalized post-vaccine infection [n = 59], non-hospitalized pre-vaccine infection [n = 68], hospitalized pre-vaccine infection [n = 18]), Quartile 2 (no infection [n = 1,069], non-hospitalized post-vaccine infection [n = 47], non-hospitalized pre-vaccine infection [n = 97], hospitalized pre-vaccine infection [n = 20]), Quartile 3 (no infection [n = 620], non-hospitalized post-vaccine infection [n = 52], non-hospitalized pre-vaccine infection [n = 119], hospitalized pre-vaccine infection [n = 32]), Quartile 4 (no infection [n = 294], non-hospitalized post-vaccine infection [n = 57], non-hospitalized pre-vaccine infection [n = 119], hospitalized pre-vaccine infection [n = 26]). B Predicted anti-S1 antibody levels by severity of acute infection generated from generalized additive model with smoothing spline since vaccination adjusted for age, sex, race/ethnicity, smoking history, education attainment, body mass index, diabetes, cardiovascular disease, asthma, chronic obstructive pulmonary disease, anti-N, dried blood spot batch, and vaccine type (n = 6,245 from multiple imputed cohort). No infection (n = 4823), non-hospitalized post-vaccine infection (n = 298), non-hospitalized pre-vaccine infection (n = 910), hospitalized pre-vaccine infection n = 214). For Fig. 4A, the bounds of the box shows the 25th and 75th percentiles, thick black line indicates the median, the vertical upper and lower whiskers extended to the largest observed data point that falls within the 1.5 × interquartile range. Black dots indicate outlier values. For Fig. 4B, lighter color bands indicate 95% confidence intervals.
